Impact of COVID-19 on rheumatic diseases in india: Determinants of mortality and adverse outcome: A retrospective, cross-sectional cohort study
Introduction: There is varying impact of COVID19 on world population depending on ethnicity, age and underlying co-morbidities. However, the lack of data regarding the effect of COVID on patients with rheumatological disorders (RDs) from different nations adds to uncertainty on disease outcome. Acr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2023;volume=18;issue=2;spage=134;epage=140;aulast=Jain |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832569103983837184 |
|---|---|
| author | Avinash Jain Vineeta Shobha S Chandrashekara Padmanabha Shenoy Sapan C Pandya Prakash Chotalia Sharath Kumar Sourabh Malviya Yogesh Preet Singh Abhishek Patil Vikas Gupta Puja Srivastava Vijaya Prasanna Parimi Chanakya Kodishala Ramya Janardana Benzeeta Pinto Sudhir Bhandari Govind Rankawat Praveen Pratap Jadhav Damodaram Potugari Vishnu Sharma Alpana Parmar Sunitha Kayidhi Paul T Antony Ashish Badika Amit Sharma |
| author_facet | Avinash Jain Vineeta Shobha S Chandrashekara Padmanabha Shenoy Sapan C Pandya Prakash Chotalia Sharath Kumar Sourabh Malviya Yogesh Preet Singh Abhishek Patil Vikas Gupta Puja Srivastava Vijaya Prasanna Parimi Chanakya Kodishala Ramya Janardana Benzeeta Pinto Sudhir Bhandari Govind Rankawat Praveen Pratap Jadhav Damodaram Potugari Vishnu Sharma Alpana Parmar Sunitha Kayidhi Paul T Antony Ashish Badika Amit Sharma |
| author_sort | Avinash Jain |
| collection | DOAJ |
| description | Introduction: There is varying impact of COVID19 on world population depending on ethnicity, age and underlying co-morbidities. However, the lack of data regarding the effect of COVID on patients with rheumatological disorders (RDs) from different nations adds to uncertainty on disease outcome. Across the world, many rheumatology associations have joined hands to collate-related information. A national database under Indian Rheumatology Associations (IRAs) was developed to understand the impact of underlying RD and immunosuppressants during the COVID pandemic on its severity and outcome in our country.
Methods: All registered members of IRA were invited to participate in this registry and provide information of reverse transcription–polymerase chain reaction confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)-infected RD patients using an online platform https://iradatabaseard.in/iracovid/index.php. The results of the data were analyzed using the appropriate statistics. Multivariate logistic regression was used to analyze the impact of different variables on mortality. Odds ratio and 95% confidence interval were used to define risk of death.
Results: In this retrospective cross-sectional study, data for 447 RD patients who were infected with SARS-CoV2 data were available as of December 1, 2020. The mean age was 47.9 ± 14.4 years, including two children and 93 (20.8%) geriatric age group patients, male: female ratio was 0.4:1 and mean disease duration was 79.3 ± 77.1 months. Rheumatoid arthritis was the most common RD. Underlying disease was quiescent in 54.7% and active in 18.4% patients. Most common medications at the time of COVID diagnosis were steroids (57.76%) and hydroxychloroquine (67.34%). Fever and cough were the most common symptoms. More than half of the patients (54.4%) needed hospitalization. Oxygen requirement was noted in 18.8%, intensive care unit admission, and invasive ventilation was needed in 6.0%, and 2.9% patients, respectively. Complete recovery was seen in 95.5% of patients and 4.47% (n = 20) expired due to COVID. The presence of comorbidity, dyspnea, and a higher neutrophil count was statistically significantly associated with death (P < 0.05). None of the other factors affected COVID-19 outcome.
Conclusion: This is the largest cohort from a single nation looking at the interface between RD and COVID. The results indicate that patients with RD do not show increased mortality despite current use of disease-modifying anti-rheumatic drugs/immunosuppressants. |
| format | Article |
| id | doaj-art-288812f031a84a9a8a8629c76ccba0dc |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-288812f031a84a9a8a8629c76ccba0dc2025-02-02T23:11:31ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012023-01-0118213414010.4103/injr.injr_278_21Impact of COVID-19 on rheumatic diseases in india: Determinants of mortality and adverse outcome: A retrospective, cross-sectional cohort studyAvinash JainVineeta ShobhaS ChandrashekaraPadmanabha ShenoySapan C PandyaPrakash ChotaliaSharath KumarSourabh MalviyaYogesh Preet SinghAbhishek PatilVikas GuptaPuja SrivastavaVijaya Prasanna ParimiChanakya KodishalaRamya JanardanaBenzeeta PintoSudhir BhandariGovind RankawatPraveen Pratap JadhavDamodaram PotugariVishnu SharmaAlpana ParmarSunitha KayidhiPaul T AntonyAshish BadikaAmit SharmaIntroduction: There is varying impact of COVID19 on world population depending on ethnicity, age and underlying co-morbidities. However, the lack of data regarding the effect of COVID on patients with rheumatological disorders (RDs) from different nations adds to uncertainty on disease outcome. Across the world, many rheumatology associations have joined hands to collate-related information. A national database under Indian Rheumatology Associations (IRAs) was developed to understand the impact of underlying RD and immunosuppressants during the COVID pandemic on its severity and outcome in our country. Methods: All registered members of IRA were invited to participate in this registry and provide information of reverse transcription–polymerase chain reaction confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)-infected RD patients using an online platform https://iradatabaseard.in/iracovid/index.php. The results of the data were analyzed using the appropriate statistics. Multivariate logistic regression was used to analyze the impact of different variables on mortality. Odds ratio and 95% confidence interval were used to define risk of death. Results: In this retrospective cross-sectional study, data for 447 RD patients who were infected with SARS-CoV2 data were available as of December 1, 2020. The mean age was 47.9 ± 14.4 years, including two children and 93 (20.8%) geriatric age group patients, male: female ratio was 0.4:1 and mean disease duration was 79.3 ± 77.1 months. Rheumatoid arthritis was the most common RD. Underlying disease was quiescent in 54.7% and active in 18.4% patients. Most common medications at the time of COVID diagnosis were steroids (57.76%) and hydroxychloroquine (67.34%). Fever and cough were the most common symptoms. More than half of the patients (54.4%) needed hospitalization. Oxygen requirement was noted in 18.8%, intensive care unit admission, and invasive ventilation was needed in 6.0%, and 2.9% patients, respectively. Complete recovery was seen in 95.5% of patients and 4.47% (n = 20) expired due to COVID. The presence of comorbidity, dyspnea, and a higher neutrophil count was statistically significantly associated with death (P < 0.05). None of the other factors affected COVID-19 outcome. Conclusion: This is the largest cohort from a single nation looking at the interface between RD and COVID. The results indicate that patients with RD do not show increased mortality despite current use of disease-modifying anti-rheumatic drugs/immunosuppressants.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2023;volume=18;issue=2;spage=134;epage=140;aulast=Jainadverse outcomeautoimmune rheumatic diseasecovid-19mortalitysevere acute respiratory syndrome coronavirus 2 infection |
| spellingShingle | Avinash Jain Vineeta Shobha S Chandrashekara Padmanabha Shenoy Sapan C Pandya Prakash Chotalia Sharath Kumar Sourabh Malviya Yogesh Preet Singh Abhishek Patil Vikas Gupta Puja Srivastava Vijaya Prasanna Parimi Chanakya Kodishala Ramya Janardana Benzeeta Pinto Sudhir Bhandari Govind Rankawat Praveen Pratap Jadhav Damodaram Potugari Vishnu Sharma Alpana Parmar Sunitha Kayidhi Paul T Antony Ashish Badika Amit Sharma Impact of COVID-19 on rheumatic diseases in india: Determinants of mortality and adverse outcome: A retrospective, cross-sectional cohort study Indian Journal of Rheumatology adverse outcome autoimmune rheumatic disease covid-19 mortality severe acute respiratory syndrome coronavirus 2 infection |
| title | Impact of COVID-19 on rheumatic diseases in india: Determinants of mortality and adverse outcome: A retrospective, cross-sectional cohort study |
| title_full | Impact of COVID-19 on rheumatic diseases in india: Determinants of mortality and adverse outcome: A retrospective, cross-sectional cohort study |
| title_fullStr | Impact of COVID-19 on rheumatic diseases in india: Determinants of mortality and adverse outcome: A retrospective, cross-sectional cohort study |
| title_full_unstemmed | Impact of COVID-19 on rheumatic diseases in india: Determinants of mortality and adverse outcome: A retrospective, cross-sectional cohort study |
| title_short | Impact of COVID-19 on rheumatic diseases in india: Determinants of mortality and adverse outcome: A retrospective, cross-sectional cohort study |
| title_sort | impact of covid 19 on rheumatic diseases in india determinants of mortality and adverse outcome a retrospective cross sectional cohort study |
| topic | adverse outcome autoimmune rheumatic disease covid-19 mortality severe acute respiratory syndrome coronavirus 2 infection |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2023;volume=18;issue=2;spage=134;epage=140;aulast=Jain |
| work_keys_str_mv | AT avinashjain impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT vineetashobha impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT schandrashekara impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT padmanabhashenoy impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT sapancpandya impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT prakashchotalia impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT sharathkumar impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT sourabhmalviya impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT yogeshpreetsingh impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT abhishekpatil impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT vikasgupta impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT pujasrivastava impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT vijayaprasannaparimi impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT chanakyakodishala impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT ramyajanardana impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT benzeetapinto impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT sudhirbhandari impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT govindrankawat impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT praveenpratapjadhav impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT damodarampotugari impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT vishnusharma impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT alpanaparmar impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT sunithakayidhi impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT paultantony impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT ashishbadika impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy AT amitsharma impactofcovid19onrheumaticdiseasesinindiadeterminantsofmortalityandadverseoutcomearetrospectivecrosssectionalcohortstudy |